ARTES Biotechnology - CDMO for Pharma and Life Science industry.

Our skills are in yeast (Hansenula, Pichia) and E. coli cell line development for recombinant peptides and proteins, highly efficient upstream and downstream process development and pilot scale manufacturing as well as technology transfer to our customers.

ARTES partners with the pharma industry for the development of vaccines and therapeutics and collaborates with the Life Science industry for products such as enzymes and structural proteins.

We value our partnership with you. Our highly experienced team is available for custom projects, offering the most efficient solution. We are experts in solving problems and setting up manufacturing processes.

All platform technologies (microbial cell line development and antigen presentation) ensure freedom-to-operate and are protected by patents and trade secrets. ARTES is available to negotiate exclusive licensing terms.

Several contract development and technology transfer projects have been successfully implemented at customer sites worldwide.

There are WHO recommendation, worldwide registrations and approvals at EMA resp. FDA and GRAS certification for enzymes. This is all part of the track record achieved in international collaborations. 

In addition, ARTES offers from its internal development ready-to-use processes for out-licensing as well as proteins, antigens and recombinant enzymes for sale as laboratory reagents.